Overview
MXCT market data
Price History
MXCT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -121.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.64 – $1.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $128M · P/B 0.96 · P/S 3.96.
Company News
8-K filing — MAXCYTE, INC. (MXCT)SEC EDGAR · Aug 12, 2026, 8:14 PM
MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $31.082M EstBenzinga · Aug 12, 2026, 8:09 PM
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M EstimateBenzinga · Aug 12, 2026, 8:09 PM
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy ProgramsBenzinga · Jul 21, 2026, 12:06 PM